Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2023-06-02 00:00:00 ET · period of report 2023-05-31 · accession 0001209191-23-033985 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-02 | 2023-05-31 | PCRX | GAUGLER DARYL | COO | M - OptEx | $34.00 | +2,500 | 26.9K | +10% | +$85.0K |
| D | 2023-06-02 | 2023-05-31 | PCRX | GAUGLER DARYL | COO | S - Sale+OE | $39.08 | -2,500 | 24.6K | -9% | -$97.7K |
| D | 2023-06-02 | 2023-05-31 | PCRX | GAUGLER DARYL | COO | M - OptEx | $0.00 | -2,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-31 | M | A | 2,500 | $34.00 | 26,894 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-31 | S | D | 2,500 | $39.08 | 24,591 | D | — | — | (F2) Includes an aggregate of 197 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022 and December 2022. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-05-31 | M | D | 2,500 | $0.00 | 0 | D | $34.00 · — to 2023-06-04 | 2,500 Common Stock | (F3) The stock option vested in equal monthly installments over one year following the grant date, provided that the reporting person remained in continuous service with the issuer as of each vesting date. |